The Indian pharmaceutical sector is witnessing a significant transformation as the incidence of cardiovascular and diabetic diseases rises sharply. According to the World Health Organization, these diseases are leading causes of mortality, with diabetes alone affecting over 80 million Indian adults, a figure anticipated to exceed 98 million by 2025. This burgeoning health crisis is fueling a surge in demand for medications, particularly in cardiac and diabetic therapies, and is spurring expansion in the pharma franchise sector. Franchise-based models offer expanded access to medicines and lucrative business opportunities across various Indian regions. Market trends such as increased disease prevalence, digital integration with telemedicine, lifestyle changes, and updated regulatory compliance are contributing to this growth. Entrepreneurs benefit from exclusive rights, diverse product offerings, and reduced risks, cementing the cardiac and diabetic pharma industry as a leader in Indian healthcare. (With inputs from agencies.)

Source: Devdiscourse